Loring Wolcott & Coolidge Fiduciary Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.48M | Sell |
27,447
-2,290
| -8% | -$192K | 0.02% | 118 |
|
|
2026
Q1 | $2.32M | Hold |
29,737
| – | – | 0.02% | 116 |
|
|
2025
Q4 | $2.49M | Sell |
29,737
-5,020
| -14% | -$412K | 0.02% | 115 |
|
|
2025
Q3 | $2.66M | Sell |
34,757
-2,170
| -6% | -$170K | 0.02% | 114 |
|
|
2025
Q2 | $2.89M | Sell |
36,927
-4,966
| -12% | -$370K | 0.03% | 108 |
|
|
2025
Q1 | $2.95M | Sell |
41,893
-11,519
| -22% | -$824K | 0.03% | 107 |
|
|
2024
Q4 | $3.7M | Sell |
53,412
-5,686
| -10% | -$398K | 0.03% | 110 |
|
|
2024
Q3 | $4.16M | Sell |
59,098
-46,746
| -44% | -$3.4M | 0.04% | 105 |
|
|
2024
Q2 | $9.29M | Sell |
105,844
-27,458
| -21% | -$2.43M | 0.09% | 70 |
|
|
2024
Q1 | $11.6M | Sell |
133,302
-52,589
| -28% | -$4.42M | 0.12% | 66 |
|
|
2023
Q4 | $14.6M | Sell |
185,891
-279,095
| -60% | -$19.4M | 0.14% | 63 |
|
|
2023
Q3 | $30.5M | Sell |
464,986
-420,027
| -47% | -$33.8M | 0.34% | 52 |
|
|
2023
Q2 | $83.5M | Sell |
885,013
-53,897
| -6% | -$4.68M | 0.89% | 31 |
|
|
2023
Q1 | $77.7M | Sell |
938,910
-31,638
| -3% | -$2.49M | 0.89% | 31 |
|
|
2022
Q4 | $72.4M | Sell |
970,548
-9,654
| -1% | -$744K | 0.9% | 30 |
|
|
2022
Q3 | $81M | Buy |
980,202
+13,709
| +1% | +$1.32M | 1.05% | 29 |
|
|
2022
Q2 | $91.9M | Buy |
966,493
+1,550
| +0.2% | +$160K | 1.13% | 27 |
|
|
2022
Q1 | $114M | Buy |
964,943
+2,140
| +0.2% | +$240K | 1.17% | 29 |
|
|
2021
Q4 | $125M | Sell |
962,803
-16,810
| -2% | -$1.96M | 1.14% | 31 |
|
|
2021
Q3 | $111M | Buy |
979,613
+2,502
| +0.3% | +$286K | 1.1% | 30 |
|
|
2021
Q2 | $101M | Sell |
977,111
-1,630
| -0.2% | -$154K | 1.02% | 31 |
|
|
2021
Q1 | $81.9M | Buy |
978,741
+11,294
| +1% | +$955K | 0.91% | 36 |
|
|
2020
Q4 | $88.3M | Buy |
967,447
+145,374
| +18% | +$12.1M | 0.99% | 33 |
|
|
2020
Q3 | $65.6M | Buy |
822,073
+317,785
| +63% | +$24.8M | 0.82% | 35 |
|
|
2020
Q2 | $34.9M | Buy |
504,288
+220,971
| +78% | +$15.7M | 0.48% | 42 |
|
|
2020
Q1 | $17.8M | Buy |
283,317
+11,196
| +4% | +$807K | 0.3% | 55 |
|
|
2019
Q4 | $21.2M | Buy |
272,121
+5,871
| +2% | +$458K | 0.29% | 58 |
|
|
2019
Q3 | $19.5M | Buy |
266,250
+18,291
| +7% | +$1.28M | 0.28% | 57 |
|
|
2019
Q2 | $15.3M | Buy |
247,959
+19,032
| +8% | +$1.15M | 0.22% | 61 |
|
|
2019
Q1 | $14.6M | Buy |
228,927
+4,107
| +2% | +$234K | 0.22% | 60 |
|
|
2018
Q4 | $11.5M | Buy |
224,820
+7,752
| +4% | +$392K | 0.21% | 65 |
|
|
2018
Q3 | $12.6M | Sell |
217,068
-2,550
| -1% | -$125K | 0.2% | 68 |
|
|
2018
Q2 | $10.7M | Buy |
219,618
+210
| +0.1% | +$9.8K | 0.19% | 71 |
|
|
2018
Q1 | $10.2M | Buy |
219,408
+178,428
| +435% | +$7.75M | 0.19% | 78 |
|
|
2017
Q4 | $1.54M | Buy |
40,980
+16,620
| +68% | +$610K | 0.03% | 140 |
|
|
2017
Q3 | $888K | Buy |
24,360
+16,032
| +193% | +$611K | 0.02% | 163 |
|
|
2017
Q2 | $320K | Buy |
8,328
+228
| +3% | +$8.32K | 0.01% | 227 |
|
|
2017
Q1 | $254K | Buy |
8,100
+6,900
| +575% | +$216K | 0.01% | 251 |
|
|
2016
Q4 | $37K | Sell |
1,200
-900
| -43% | -$29.2K | ﹤0.01% | 420 |
|
|
2016
Q3 | $84K | Hold |
2,100
| – | – | ﹤0.01% | 350 |
|
|
2016
Q2 | $70K | Buy |
2,100
+1,200
| +133% | +$41.1K | ﹤0.01% | 362 |
|
|
2016
Q1 | $26K | Hold |
900
| – | – | ﹤0.01% | 461 |
|
|
2015
Q4 | $24K | Hold |
900
| – | – | ﹤0.01% | 496 |
|
|
2015
Q3 | $21K | Hold |
900
| – | – | ﹤0.01% | 486 |
|
|
2015
Q2 | $21K | Hold |
900
| – | – | ﹤0.01% | 486 |
|
|
2015
Q1 | $21K | Hold |
900
| – | – | ﹤0.01% | 502 |
|
|
2014
Q4 | $19K | Hold |
900
| – | – | ﹤0.01% | 503 |
|
|
2014
Q3 | $15K | Hold |
900
| – | – | ﹤0.01% | 500 |
|
|
2014
Q2 | $13K | Hold |
900
| – | – | ﹤0.01% | 537 |
|
|
2014
Q1 | $11K | Buy |
+900
| New | +$10.4K | ﹤0.01% | 541 |
|
|
2013
Q4 | – | Sell |
-3,120
| Closed | -$36K | – | 601 |
|
|
2013
Q3 | $36K | Sell |
3,120
-1,200
| -28% | -$14K | ﹤0.01% | 393 |
|
|
2013
Q2 | $48K | Buy |
+4,320
| New | +$51.1K | ﹤0.01% | 389 |
|
Other funds holding EW
WT
N
Loring Wolcott & Coolidge Fiduciary Advisors's EW Position: Q2 2026 in Review
Loring Wolcott & Coolidge Fiduciary Advisors reduced its Edwards Lifesciences (EW) stake by 7.7% in Q2 2026, selling an estimated $192K and leaving 27,447 shares worth $2.48M. The position accounts for 0.02% of the portfolio, ranked #118.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $125M in Q4 2021. 896 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Loring Wolcott & Coolidge Fiduciary Advisors held 27,447 shares of Edwards Lifesciences worth $2.48M as of Q2 2026.
- Loring Wolcott & Coolidge Fiduciary Advisors sold 2,290 Edwards Lifesciences shares in Q2 2026, an estimated $192K.
- Edwards Lifesciences made up 0.02% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #118 holding.
- Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Loring Wolcott & Coolidge Fiduciary Advisors's Edwards Lifesciences position peaked at $125M in Q4 2021.
- 896 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.